Comparison of anti-human T cell globulins on immune reconstitution and early infections after autologous transplant in patients with multiple sclerosis - Scorecard - MDSpire
Advertisement
Comparison of anti-human T cell globulins on immune reconstitution and early infections after autologous transplant in patients with multiple sclerosis
Clinical Scorecard: Evaluation of Anti-Human T Cell Globulins on Immune Recovery and Initial Infections Following Autologous Transplantation in Multiple Sclerosis Patients
At a Glance
Category
Detail
Condition
Multiple sclerosis (MS), an autoimmune central nervous system disease
Key Mechanisms
Autologous hematopoietic stem cell transplantation (AHSCT) with lymphodepleting serotherapy (cyclophosphamide plus anti-thymocyte globulin or anti-T-lymphocyte globulin) to reset immune system
Target Population
Patients with relapsed-remitting, primary-progressive, or secondary-progressive MS undergoing first AHSCT
Care Setting
Specialized transplant centers performing AHSCT with serotherapy conditioning regimens
Key Highlights
AHSCT with cyclophosphamide and ATG or ATLG is recommended for treatment-resistant or aggressive MS.
ATG is rabbit-derived polyclonal IgG against human thymocytes; ATLG targets activated T cells (Jurkat line).
Pre-transplant ATLG leads to faster immune reconstitution at day 30 compared to post-transplant ATG.
Guideline-Based Recommendations
Diagnosis
MS diagnosis based on clinical subtype (RRMS, PPMS, SPMS) and treatment resistance or aggressiveness.
Management
Use cyclophosphamide-based conditioning with either ATG or ATLG serotherapy for AHSCT in MS patients.
Select serotherapy regimen based on institutional protocols and availability.
Monitoring & Follow-up
Perform peripheral blood lymphocyte immunophenotyping at days +30 and +100 post-AHSCT to assess immune reconstitution.
Monitor for EBV and CMV reactivation using PCR assays with defined viral load thresholds.
Risks
Early infectious complications post-AHSCT require monitoring; rehospitalization and intensive care may be necessary.
Variation in serotherapy dosing and schedule may impact immune recovery and infection risk.
Patient & Prescribing Data
63 MS patients (RRMS, PPMS, SPMS) undergoing first AHSCT with cyclophosphamide plus ATG or ATLG.
42 patients received ATG (mostly post-transplant dosing), 21 received ATLG (mostly pre-transplant dosing); pre-transplant ATLG associated with faster T cell recovery at day 30.
Clinical Best Practices
Administer cyclophosphamide 50 mg/kg daily for 4 days prior to AHSCT.
Consider pre-transplant ATLG dosing (30 mg/kg escalating doses days −4 to −1) for enhanced early immune recovery.
Use flow cytometry to monitor T cell subsets and immune reconstitution post-transplant.
Regularly assess EBV and CMV viral loads to detect and manage viral reactivations early.
Tailor serotherapy choice and dosing schedule to institutional protocols and patient-specific factors.
by Johanna Richter, Nico Gagelmann, Felix Fischbach, Kristin Rathje, Lena Kristina Pfeffer, Boris Fehse, Anita Badbaran, Susanna Carolina Berger, Rolf Krause, Evgeny Klyuchnikov, Christine Wolschke, Catherina Lueck, Francis Ayuk, Manuel A. Friese, Christoph Heesen, Nicolaus Kröger
